Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
400 participants
INTERVENTIONAL
2021-09-01
2025-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Polypharmacy Outpatient Clinic
NCT03911934
Prioritising Patient Medication Review: Hospitals Reaching Out
NCT06451692
Improving Compliance Among Elderly Polypharmacy Users Through Community Pharmacy Based Pharmaceutical Care Program
NCT00916214
MODIFY or Medication Review in Primary Care Study
NCT05705284
Reduction of Polypharmacy in Elderly People With Multiple Diseases
NCT05526963
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The hypothesis is that the regional intervention delivered by the pharmacists, from Nord-KAP, can lead to a decrease in medical products compared with a control group between baseline and at 6-month follow-up.
* Will the use of a pharmacists intervention lead to a decrease in the number of polypharmacy patients in medical clinics compared to a control group of medical clinics?
* Will the use of a pharmacist intervention lead to an increase in the polypharmacy patients health-related quality of life compared to a control group?
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention group - Medical clinics
Medical clinics receiving the pharmacist intervention described in the intervention group for patient level
Systematic pharmacist intervention
Already described in the arm group intervention group for patient level
Control group - medical clinics
All medical clinics that are enrolled in the trial will eventually receive the intervention at some point. As some medical clinics act as the control group to being with.
No interventions assigned to this group
Intervention group - patient level
The intervention consists of two subgroups: Intervention pharmacist and intervention proposals. As the pharmacist conducts medication reviews of the polypharmacy patients in the medical clinic they can make a note to the physician about fx a specific medication the physician needs to pay attention to. These polypharmacy patients are enrolled in the group intervention proposals and are asked to complete questionaries at baseline and follow-up. Ultimately, it is up to the physician to react to the note in the polypharmacy patients medical record. Therefore the pharmacist only makes a note in the journal of the patient and does nothing else.
The group intervention pharmacist is polypharmacy patients where the pharmacist conducts a medication review and develops suggested interventions proposals for each participant
Systematic pharmacist intervention
Already described in the arm group intervention group for patient level
Control group - patient level
The control group will have access to usual care and other health services within the healthcare systems. Participants randomised to the control group are invited to participate in the evaluation of the current treatment in the primary health care sector
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Systematic pharmacist intervention
Already described in the arm group intervention group for patient level
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Above 18 years
* Patients in continuous medication treatment
Exclusion Criteria
* Patients who are not motivated to comply with the instruction of the trial
* Do not speak/or understand written Danish
* Patients lacking legal capacity
* Patients living at nursing homes
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Quality Unit for General Practice North Denmark Region
UNKNOWN
Aalborg University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Josefine Mikkelsen
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The quality unit for genreal practice
Aalborg, North Denmark, Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
Link to the homepage of the pharmacist intervention from the quality unit for general practice north denmark region
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Aalborg University
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.